-
EP3171891
European procedure
Extract from the Register of European Patents
EP About this file: EP3171891
| EP3171891 - METHOD [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 08.08.2025 Database last updated on 08.04.2026 | |
| Former | Grant of patent is intended Status updated on 20.01.2025 | ||
| Former | Examination is in progress Status updated on 17.08.2019 | ||
| Former | Request for examination was made Status updated on 28.04.2017 | ||
| Former | The international publication has been made Status updated on 11.02.2017 | Most recent event Tooltip | 05.09.2025 | Change - divisional application(s) | published on 08.10.2025 [2025/41] | Applicant(s) | For all designated states Hansa Biopharma AB Box 785 220 07 Lund / SE | [2025/37] |
| Former [2019/46] | For all designated states Hansa Bipopharma AB Box 785 220 07 Lund / SE | ||
| Former [2017/22] | For all designated states Hansa Medical AB P.O. Box 785 220 07 Lund / SE | Inventor(s) | 01 /
KJELLMAN, Christian c/o Hansa Medical AB PO Box 785 SE 220 07 Lund / SE | 02 /
JARNUM, Sofia c/o Hansa Medical AB PO Box 785 SE 220 07 Lund / SE | 03 /
WINSTEDT, Lena c/o Hansa Medical AB PO Box 785 SE 220 07 Lund / SE | [2017/22] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2025/37] |
| Former [2017/22] | Lewis, Graham Matthew J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | Application number, filing date | 15756845.2 | 10.07.2015 | [2017/22] | WO2015EP65895 | Priority number, date | GB20140013240 | 25.07.2014 Original published format: GB 201413240 | [2017/22] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2016012285 | Date: | 28.01.2016 | Language: | EN | [2016/04] | Type: | A2 Application without search report | No.: | EP3171891 | Date: | 31.05.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.01.2016 takes the place of the publication of the European patent application. | [2017/22] | Type: | B1 Patent specification | No.: | EP3171891 | Date: | 10.09.2025 | Language: | EN | [2025/37] | Search report(s) | International search report - published on: | EP | 14.04.2016 | Classification | IPC: | A61K39/395, C12N9/24 | [2017/22] | CPC: |
A61K38/4873 (EP,IL,KR,US);
C12N9/52 (EP,IL,KR,US);
A61K35/22 (IL,US);
A61K38/47 (KR);
A61K39/395 (IL,US);
A61P35/00 (EP,IL,KR);
A61P35/02 (EP,IL);
A61P37/06 (EP,IL);
A61P43/00 (EP,IL);
C07K14/195 (KR);
C07K14/315 (KR);
C07K14/34 (KR);
C07K16/00 (EP,IL,US);
C12N9/24 (IL);
C12N9/2402 (EP,IL,KR,US);
C12Y302/01096 (EP,IL,US);
G01N33/686 (IL);
A61K2039/505 (IL);
A61K2039/545 (IL);
C07K2317/21 (EP,IL,US);
C07K2317/52 (EP,IL,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/22] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | Title | German: | VERFAHREN | [2017/22] | English: | METHOD | [2017/22] | French: | PROCÉDÉ | [2017/22] | Entry into regional phase | 10.02.2017 | National basic fee paid | 10.02.2017 | Designation fee(s) paid | 10.02.2017 | Examination fee paid | Examination procedure | 10.02.2017 | Examination requested [2017/22] | 10.02.2017 | Date on which the examining division has become responsible | 15.09.2017 | Amendment by applicant (claims and/or description) | 21.08.2019 | Despatch of a communication from the examining division (Time limit: M06) | 26.02.2020 | Reply to a communication from the examining division | 06.11.2020 | Despatch of a communication from the examining division (Time limit: M06) | 13.05.2021 | Reply to a communication from the examining division | 13.03.2024 | Despatch of a communication from the examining division (Time limit: M04) | 10.07.2024 | Reply to a communication from the examining division | 21.01.2025 | Communication of intention to grant the patent | 06.06.2025 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time | 05.08.2025 | Fee for grant paid | 05.08.2025 | Fee for publishing/printing paid | 05.08.2025 | Receipt of the translation of the claim(s) | Divisional application(s) | EP25199052.9 | Request for further processing for: | The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent | 05.08.2025 | Request for further processing filed | 05.08.2025 | Full payment received (date of receipt of payment) Request granted | 11.08.2025 | Decision despatched | Fees paid | Renewal fee | 12.07.2017 | Renewal fee patent year 03 | 11.07.2018 | Renewal fee patent year 04 | 15.07.2019 | Renewal fee patent year 05 | 14.07.2020 | Renewal fee patent year 06 | 15.07.2021 | Renewal fee patent year 07 | 15.06.2022 | Renewal fee patent year 08 | 14.06.2023 | Renewal fee patent year 09 | 30.05.2024 | Renewal fee patent year 10 | 13.06.2025 | Renewal fee patent year 11 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XYI] WO2013110946 (CRISPIN MATTHEW DAVID MAX et al.) | [Y] WO2008071418 (HANSA MEDICAL AB et al.) | [I] WO2013037824 (GENOVIS AB et al.) | [I] WO2009033670 (GENOVIS AB et al.) | [IY] KAVITHA BARUAH ET AL: "Selective Deactivation of Serum IgG: A General Strategy for the Enhancement of Monoclonal Antibody Receptor Interactions", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 420, no. 1, 3 April 2012 (2012-04-03), pages 1 - 7, XP028514772, ISSN: 0022-2836, [retrieved on 20120405], DOI: 10.1016/J.JMB.2012.04.002 DOI: http://dx.doi.org/10.1016/j.jmb.2012.04.002 | [IY] KUTTY SELVA NANDAKUMAR ET AL: "Blocking of experimental arthritis by cleavage of IgG antibodies in vivo", ARTHRITIS & RHEUMATISM, vol. 56, no. 10, 1 January 2007 (2007-01-01), pages 3253 - 3260, XP055107646, ISSN: 0004-3591, DOI: 10.1002/art.22930 DOI: http://dx.doi.org/10.1002/art.22930 | [A] ALBERT HEIKE ET AL: "In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 105, no. 39, 30 September 2008 (2008-09-30), pages 15005 - 15009, XP002569095, ISSN: 0027-8424, [retrieved on 20080924], DOI: 10.1073/PNAS.0808248105 DOI: http://dx.doi.org/10.1073/PNAS.0808248105 | [I] JENNY JOHANSSON SDERBERG: "The streptococcal IgG degrading enzyme IdeS -studies on host-pathogen interactions", 1 January 2012 (2012-01-01), XP055248265, Retrieved from the Internet | [XY] ANONYMOUS: "Structural Biochemistry/Proteins/Enzyme-Linked Immunoabsorbent Assay (ELISA) - Wikibooks, open books for an open world", 29 October 2012 (2012-10-29), XP055248514, Retrieved from the Internet | Examination | WO2006131347 | BJRN P JOHANSSON ET AL: "IdeS: A Bacterial Proteolytic Enzyme with Therapeutic Potential", PLOS ONE, vol. 3, no. 2, 1 February 2008 (2008-02-01), pages e1692, XP055574727, DOI: 10.1371/journal.pone.0001692 DOI: http://dx.doi.org/10.1371/journal.pone.0001692 | DANIEL R GETTS ET AL: "Current landscape for T-cell targeting in autoimmunity and transplantation", IMMUNOTHERAPY, vol. 3, no. 7, 1 July 2011 (2011-07-01), GB, pages 853 - 870, XP055246670, ISSN: 1750-743X, DOI: 10.2217/imt.11.61 DOI: http://dx.doi.org/10.2217/imt.11.61 | by applicant | US4366241 | ACKERMAN, M.E.; B. MOLDT; R.T. WYATT; A.S. DUGAST; E. MCANDREW; S. TSOUKAS; S. JOST; C.T. BERGER; G. SCIARANGHELLA; Q. LIU: "A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples", JIMMUNOL METHODS, vol. 366, 2011, pages 8 - 19 | AGNISWAMY, J.; B. LEI; J.M. MUSSER; P.D. SUN: "Insight of host immune evasion mediated by two variants of group a Streptococcus Mac protein", JBIOL CHEM, vol. 279, 2004, pages 52789 - 52796 | BREZSKI, R.J.; O. VAFA; D. PETRONE; S.H. TAM; G. POWERS; M.H. RYAN; J.L. LUONGO; A. OBERHOLTZER; D.M. KNIGHT; R.E. JORDAN: "Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge", PROC NATL ACAD SCI U SA, vol. 106, 2009, pages 17864 - 17869 | CARAPETIS, J.R.; A.C. STEER; E.K. MULHOLLAND; M. WEBER.: "The global burden of group A streptococcal diseases", LANCET INFECT DIS, vol. 5, 2005, pages 685 - 694 | COLLEN, D.; F. DE COCK; E. DEMARSIN; S. JENNE; I. LASTERS; Y. LAROCHE; P. WARMERDAM; L. JESPERS: "Recombinant staphylokinase variants with altered immunoreactivity. III: Species variability of antibody binding patterns", CIRCULATION, vol. 95, 1997, pages 455 - 462 | DECLERCK, P.J.; S. VANDERSCHUEREN; J. BILLIET; H. MOREAU; D. COLLEN: "Prevalence and induction of circulating antibodies against recombinant staphylokinase", THROMB HAEMOST, vol. 71, 1994, pages 129 - 133 | ISMAIL, N.; R. NEYRA; R. HAKIM: "Handbook of dialysis", 2001, article "Plasmapheresis", pages: 231 - 262 | IYER, S.P.; L.E. NIKKEL; K.K. NISHIYAMA; E. DWORAKOWSKI; S. CREMERS; C. ZHANG; D.J. MCMAHON; S. BOUTROY; X.S. LIU; L.E. RATNER: "Kidney Transplantation with Early Corticosteroid Withdrawal: Paradoxical Effects at the Central and Peripheral Skeleton", JAM SOC NEPHROL, 2014 | JOHANSSON, B.P.; O. SHANNON; L. BJORCK: "IdeS: a bacterial proteolytic enzyme with therapeutic potential", PLOS ONE, vol. 3, 2008, pages E1692 | JORDAN, S.C.; D. TYAN; D. STABLEIN; M. MCINTOSH; S. ROSE; A. VO; M. TOYODA; C. DAVIS; R. SHAPIRO; D. ADEY: "Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.", JAM SOC NEPHROL, vol. 15, 2004, pages 3256 - 3262 | KARLSSON, C.; L. MALMSTROM; R. AEBERSOLD; J. MALMSTROM: "Proteome-wide selected reaction monitoring assays for the human pathogen Streptococcus pyogenes", NAT COMMUN, vol. 3, 2012, pages 1301 | MACLEAN, B.; D.M. TOMAZELA; N. SHULMAN; M. CHAMBERS; G.L. FINNEY; B. FREWEN; R. KERN; D.L. TABB; D.C. LIEBLER; M.J. MACCOSS: "Skyline: an open source document editor for creating and analyzing targeted proteomics experiments", BIOINFORMATICS, vol. 26, 2010, pages 966 - 968 | MAINET, D.; M. DEL ROSARIO; A. TORUNCHA; P. PRATS; C. VALENZUELA; P. LOPEZ SAURA: "Similar, more than 6-months persisted, antibody and neutralizing activity responses in patients with acute myocardial infarction treated with recombinant or natural streptokinase", FIBRINOLYSIS PROTEOL, vol. 12, 1998, pages 301 - 309 | MONTGOMERY, R.A.; A.A. ZACHARY; L.C. RACUSEN; M.S. LEFFELL; K.E. KING; J. BURDICK; W.R. MALEY; L.E. RATNER: "Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients", TRANSPLANTATION, vol. 70, 2000, pages 887 - 895 | NANDAKUMAR, K.S.; B.P. JOHANSSON; L. BJORCK; R. HOLMDAHL: "Blocking of experimental arthritis by cleavage of IgG antibodies in vivo", ARTHRITIS RHEUM, vol. 56, 2007, pages 3253 - 3260 | OJO, A.O.; R.A. WOLFE; P.J. HELD; F.K. PORT; R.L. SCHMOUDER: "Delayed graft function: risk factors and implications for renal allograft survival", TRANSPLANTATION, vol. 63, 1997, pages 968 - 974 | RYAN, M.H.; D. PETRONE; J.F. NEMETH; E. BARNATHAN; L. BJORCK; R.E. JORDAN: "Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid", MOL IMMUNOL, vol. 45, 2008, pages 1837 - 1846 | TELEMAN, J.; S. WALDEMARSON; J. MALMSTROM; F. LEVANDER: "Automated quality control system for LC-SRM setups", JPROTEOMICS, vol. 95, 2013, pages 77 - 83 | TRADTRANTIP, L.; N. ASAVAPANUMAS; A.S. VERKMAN: "Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase", MOL PHARMACOL, vol. 83, 2013, pages 1268 - 1275 | WENIG, K.; L. CHATWELL; U. VON PAWEL-RAMMINGEN; L. BJORCK; R. HUBER; P. SONDERMANN: "Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG", PROC NATL ACAD SCI USA, vol. 101, 2004, pages 17371 - 17376 | VINCENTS, B.; U. VON PAWEL-RAMMINGEN; L. BJORCK; M. ABRAHAMSON: "Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding", BIOCHEMISTRY, vol. 43, 2004, pages 15540 - 15549 | VINDEBRO, R.; C. SPOERRY; U. VON PAWEL-RAMMINGEN: "Rapid IgG heavy chain cleavage by the streptococcal IgG endopeptidase IdeS is mediated by IdeS monomers and is not due to enzyme dimerization", FEBS LETT, vol. 587, 2013, pages 1818 - 1822 | VO, A.A.; M. LUKOVSKY; M. TOYODA; J. WANG; N.L. REINSMOEN; C.H. LAI; A. PENG; R. VILLICANA; S.C. JORDAN: "Rituximab and intravenous immune globulin for desensitization during renal transplantation", N ENGL J MED, vol. 359, 2008, pages 242 - 251 | VO, A.A.; E.A. WECHSLER; J. WANG; A. PENG; M. TOYODA; M. LUKOVSKY, N. REINSMOEN; S.C. JORDAN: "Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab", AM J TRANSPLANT, vol. 8, 2008, pages 144 - 149 | VON PAWEL-RAMMINGEN, U.; B.P. JOHANSSON; L. BJORCK: "IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G.", EMBO J, vol. 21, 2002, pages 1607 - 1615 | VON PAWEL-RAMMINGEN, U.; B.P. JOHANSSON; H. TAPPER; L. BJORCK: "Streptococcus pyogenes and phagocytic killing", NAT MED, vol. 8, 2002, pages 1044 - 1045 | YANG, R.; M.A. OTTEN; T. HELLMARK; M. COLLIN; L. BJORCK; M.H. ZHAO; M.R. DAHA; M. SEGELMARK.: "Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes", NEPHROL DIAL TRANSPLANT, vol. 25, 2010, pages 2479 - 2486 | AKESSON, P.; M. RASMUSSEN; E. MASCINI; U. VON PAWEL-RAMMINGEN; R. JANULCZYK; M. COLLIN; A. OLSEN; E. MATTSSON; M.L. OLSSON; L. BJO: "Low antibody levels against cell wall-attached proteins of Streptococcus pyogenes predispose for severe invasive disease", J INFECT DIS, vol. 189, 2004, pages 797 - 804 | DING JW; ZHOU T; ZENG H; MA L; VERBEEK JS; YIN D: "m.fl. Hyperacute rejection by anti-Gal IgGl, IgG2a, and IgG2b is dependent on complement and Fc-gamma receptors", J IMMUNOL., vol. 180, no. 1, 1 January 2008 (2008-01-01), pages 261 - 8 | JORDAN SC; VO A; BUNNAPRADIST S; TOYODA M; PENG A; PULIYANDA D; KAMIL E; TYAN D: "Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients", TRANSPLANTATION, vol. 76, no. 4, August 2003 (2003-08-01), pages 631 - 636 | MOLL S; PASCUAL M: "Humoral rejection of organ allografts", AM. J. TRANSPLANT, vol. 5, November 2005 (2005-11-01), pages 2611 - 2618 | MONTGOMERY RA; HARDY MA; JORDAN SC; RACUSEN LC; RATNER LE; TYAN DB; ZACHARY AA: "Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols", TRANSPLANTATION, vol. 78, no. 2, July 2004 (2004-07-01), pages 181 - 185 | "Organ Procurement and Transplantation Network (OPTN) Database", 11 May 2011, HEALTH RESOURCES AND SERVICES ADMINISTRATION | THOMAS B. MARTINS, DEVELOPMENT OF INTERNAL CONTROLS FOR THE LUMINEX INSTRUMENT AS PART OF A MULTIPLEX SEVEN-ANALYTE VIRAL RESPIRATORY ANTIBODY PROFILE | PATEL R; TERASAKI PI: "Significance of the positive crossmatch test in kidney transplantatio", N. ENGL. J. MED., vol. 280, no. 14, April 1969 (1969-04-01), pages 735 - 739 | PIERSON RN 3RD.: "Antibody-mediated xenograft injury: mechanisms and protective strategies", TRANSPL IMMUNOL, vol. 21, no. 2, June 2009 (2009-06-01), pages 65 - 9 | TERASAKI PI; OZAWA M: "Predicting kidney graft failure by HLA antibodies: a prospective trial", AM. J. TRANSPLANT, vol. 4, no. 3, March 2004 (2004-03-01), pages 438 - 443 | VO AA; PETROZZINO J; YEUNG K; SINHA A; KAHWAJI J; PENG A: "m.fl. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab", TRANSPLANTATION, vol. 95, no. 6, 27 March 2013 (2013-03-27), pages 852 - 8 | VON PAWEL-RAMMINGEN U; JOHANSSON BP; BJORCK L: "IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G", EMBO J, vol. 21, no. 7, April 2002 (2002-04-01), pages 1607 - 1615 | AKESSON P; MORITZ L; TRUEDSSON M, CHRISTENSSON B; VON PAWEL-RAMMINGEN U: "IdeS, a highly specific immunoglobulin G (IgG)-cleaving enzyme from Streptococcus pyogenes, is inhibited by specific IgG antibodies generated during infection", INFECT. IMMUN, vol. 74, no. 1, January 2006 (2006-01-01), pages 497 - 503 | AVALOS A. M.; PLOEGH H.: "Early BCR Events and Antigen Capture, Processing and Loading on MHC Class II on B cells", FRONT. IMMUNOL., vol. 10, no. 5, March 2014 (2014-03-01), pages 92 | DAL PORTO JM; GAULD SB; MERRELL KT; MILLS D; PUGH-BERNARD AE; CAMBIER J.: "B cell antigen receptor signaling 101", MOL. IMMUNOL., vol. 41, no. 6-7, 2004, pages 599 - 613 | DOBBS AK; YANG T; FARMER D; KAGER L; PAROLINI O; CONLEY ME.: "Cutting edge: a hypomorphic mutation in Igbeta (CD79b) in a patient with immunodeficiency and a leaky defect in B cell development", J IMMUNOL., vol. 179, no. 4, 15 December 2006 (2006-12-15), pages 2055 - 9 | HARDY I; ANCERIZ N; ROUSSEAU F; SEEFELDT M; IRLA M ET AL.: "Anti-CD79 Antibody Induces B Cell Anergy That Protects against Autoimmunity", J IMMUNOL., vol. 192, 2014, pages 1641 - 1650 | JAHNMATZ M; KESA G; NETTERLID E; BUISMAN AM; THORSTENSSON R ET AL.: "Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell responses", J IMMUNOL METHODS, vol. 391, 2013, pages 50 - 59 | JOHANSSON BP; SHANNON O; BJORCK L: "IdeS: a bacterial proteolytic enzyme with therapeutic potential", PLOS ONE, vol. 3, 2008, pages EL692 | JOHNSON GL; LAPADAT R: "Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases", SCIENCE, vol. 298, 2002, pages 1911 - 1912 | KUROSAKI T: "Regulation of B-cell signal transduction by adaptor proteins", NAT. REV. IMMUNOL., vol. 2, no. 5, 2002, pages 354 - 363 | LANZAVECCHIA A: "Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes", ANNU REV IMMUNOL, vol. 8, 1990, pages 773 - 93 | MANZ R; HAUSER A; HIEPE F; RADBRUCH A.: "Maintenance Of Serum Antibody Levels", ANNU. REV. IMMUNOL., vol. 23, 2005, pages 367 - 86 | NANDAKUMAR KS; JOHANSSON BP; BJORCK L; HOLMDAHL R: "Blocking of experimental arthritis by cleavage of IgG antibodies in vivo", ARTHRITIS RHEUM, vol. 56, 2007, pages 3253 - 3260 | RAJEWSKY K.: "Clonal selection and learning in the antibody system", NATURE, vol. 381, no. 6585, 1996, pages 751 - 8 | RETH M: "Antigen receptor tail clue", NATURE, vol. 338, no. 6214, 1989, pages 383 - 384 | RETH M; WIENANDS J: "Initiation and processing of signals from the B cell antigen receptor", ANNU. REV. IMMUNOL., vol. 15, 1997, pages 453 - 479 | SCHARENBERG AM; HUMPHRIES LA; RAWLINGS DJ: "Calcium signalling and cell-fate choice in B cells", NAT. REV. IMMUNOL, vol. 7, no. 10, 2007, pages 778 - 789 | STUART G. TANGYE; KIM L.: "Good Human IgM+CD27+ B Cells: Memory B Cells or ''Memory'' B Cells?", THE JOURNAL O/1MMUNO/OGV, vol. 179, 2007, pages 13 - 19 | SU YF; CHUANG WJ; WANG SM; CHEN WY; CHIANG-NI C; LIN YS; WU JJ; LIU CC: "The deficient cleavage of M protein-bound IgG by IdeS: insight into the escape of Streptococcus pyogenes from antibody-mediated immunity", MOL IMMUNOL., vol. 49, no. 1-2, 2011, pages 134 - 42 | TANGYE; TRALINGTON: "Memory B cells: Effectors of long-lived immune responses", EUR. J. IMMUNOL., vol. 39, 2009, pages 2065 - 2075 | TRADTRANTIP L; ASAVAPANUMAS N; VERKMAN AS: "Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase", MOL PHARMACOL, vol. 83, 2013, pages 1268 - 1275 | VINCENTS B; VON PAWEL-RAMMINGEN U; BJORCK L; ABRAHAMSON M: "Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding", BIOCHEMISTRY, vol. 43, 2004, pages 15540 - 9 | VON PAWEL-RAMMINGEN U; JOHANSSON B P; BJORCK L: "IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G", EMBO J, vol. 21, 2002, pages 1607 - 15 | WENIG K; CHATWELL L; VON PAWEL-RAMMINGEN U; BJORCK L; HUBER R; SONDERMANN P: "Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG", PROC NATL ACAD SCI USA, vol. 101, 2004, pages 17371 - 6 | YANG R; OTTEN MA; HELLMARK T; COLLIN M; BJORCK L ET AL.: "Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes", NEPHROL DIAL TRANSPLANT, vol. 25, 2010, pages 2479 - 2486 |